ArticleJHLT open2026
Five-year competing-risk analysis of infectious and noninfectious complications after lung transplantation: Real-world evidence from a multicenter EHR-based cohort.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the 5-year incidence of major post-transplant outcomes using a competing-risks framework. We analyzed data from 10,648 lung transplantation (LTx) recipients using the TriNetX U.S. Collaborative Network (January 1, 2015, to December 31, 2024). The Aalen-Johansen method was used to estimate the cumulative incidence function (CIF) of post-transplant complications. Infectious complications had the highest 5-year CIF (30.88%) and steepest annual trend (5.79%), slightly exceeding noninfectious complications (30.28%, 5.69%). Mortality reached 10.62%, and malignancies 6.72%. Cytomegalovirus showed the highest infectious burden (CIF 17.02%, annual trend 3.40%), with a steep rise within the first 180 days. Bacterial pneumonia followed a slower but sustained trajectory (CIF 9.1%, 1.8% annually). Statistical analyses confirmed significant differences across all outcomes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.